Nimbolide / NRF2 Cancer Research Results

Nimb, Nimbolide: Click to Expand ⟱
Features:
Nimbolide is a compound found in the neem tree (Azadirachta indica) and has been studied for its potential anti-cancer properties. nimbolide is a neem-derived tetranortriterpenoid limonoid from Azadirachta indica.

Research has shown that nimbolide has anti-proliferative and pro-apoptotic effects on various types of cancer cells, including breast, lung, colon, and prostate cancer cells. It has also been shown to inhibit the growth of cancer cells by inducing cell cycle arrest and apoptosis (programmed cell death).

Some of the ways in which nimbolide may help to prevent or treat cancer include:
-Inhibiting the activity of certain enzymes that are involved in cancer cell growth and survival
-Inducing the production of reactive oxygen species (ROS) that can damage cancer cells
-Inhibiting the formation of new blood vessels that are needed to support the growth of cancer cells
-Enhancing the effectiveness of chemotherapy and radiation therapy

Nimbolide — Nimbolide is a neem-derived tetranortriterpenoid limonoid from Azadirachta indica with preclinical anticancer activity across multiple tumor models. It is best classified as a small-molecule plant limonoid / electrophilic triterpenoid natural product rather than as “neem oil” or whole neem extract. Standard abbreviation is NB or NL. aliases: “neem limonoids,” “neem extract,” and “Azadirachta indica limonoids”

Primary mechanisms (ranked):

  1. Covalent modulation of the ubiquitin-proteasome axis, especially RNF114-dependent substrate recognition and p21 stabilization.
  2. Mitochondrial oxidative stress induction through ROS elevation and SOD2 suppression in susceptible cancer cells.
  3. Apoptosis activation through caspase signaling, mitochondrial stress, and survival-pathway suppression.
  4. STAT3 and NF-κB pathway inhibition, reducing inflammatory survival signaling, proliferation, invasion, and anti-apoptotic transcription.
  5. EMT, migration, invasion, angiogenesis, and metastasis suppression in preclinical models.
  6. Autophagy modulation, including inhibition of cytoprotective autophagy in some tumor contexts.
  7. DNA damage response leverage, including RNF114-linked PARP1 trapping and reported synthetic-lethality relevance in BRCA-mutated models.

Bioavailability / PK relevance: Nimbolide is hydrophobic and poorly water-soluble, so systemic translation is constrained by formulation, solubility, exposure, metabolism, and tissue delivery. Nanoparticle and carrier-based formulations are being explored preclinically to improve delivery and anticancer exposure.

In-vitro vs systemic exposure relevance: Most anticancer findings use purified nimbolide in cell culture or animal models; direct equivalence to oral neem preparations is not established. Common in-vitro low-micromolar activity should not be assumed achievable with dietary or crude neem exposure. Whole neem oil or extract is chemically heterogeneous and may not deliver predictable nimbolide exposure.

Clinical evidence status: Preclinical. Evidence is strong enough for a database entry as a mechanistically interesting anticancer natural product, but not as a clinically validated anticancer therapy. No approved oncology indication or clear nimbolide-specific cancer trial status was identified; clinical use should be treated as unsupported outside research contexts.

Nimbolide Cancer Mechanism Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 RNF114 ubiquitin ligase axis RNF114 substrate recognition ↓; p21 stabilization ↑; proliferation ↓ Likely context-dependent; selectivity depends on dependency on RNF114-regulated substrates R/G Cell-cycle suppression and targeted-protein-degradation relevance High mechanistic importance because nimbolide has a defined electrophilic target interaction and can be used as a covalent recruiter scaffold.
2 Mitochondrial ROS and SOD2 ROS ↑; SOD2 ↓; mitochondrial stress ↑; apoptosis ↑ Potential oxidative-stress risk at sufficient exposure; selectivity is model-dependent R/G Oxidative apoptosis and metastasis suppression Core in pancreatic cancer models; may be especially relevant where tumor cells depend on antioxidant buffering.
3 Apoptosis and caspase activation Caspase 3 ↑; caspase 8 ↑; caspase 9 ↑; survival ↓ Lower effect reported in some normal-cell comparisons, but not universally established G Programmed cell death induction Central downstream phenotype across many cancer models.
4 STAT3 inflammatory survival signaling STAT3 phosphorylation ↓; anti-apoptotic transcription ↓; invasion ↓ Could suppress normal inflammatory or repair signaling if systemic exposure is high R/G Reduced proliferation, survival, and metastatic signaling Important in prostate and pancreatic cancer contexts; likely intersects with ROS and NF-κB effects.
5 NF-κB and Wnt beta catenin NF-κB activation ↓; IκB degradation ↓; Wnt beta catenin signaling ↓ Potential immune and epithelial-homeostasis effects are context-dependent R/G Anti-inflammatory, anti-survival, and anti-proliferative signaling Broadly reported in neem/nimbolide literature, but pathway dominance varies by tumor model.
6 Autophagy survival axis Cytoprotective autophagy ↓; apoptosis ↑ Autophagy effects may be protective or harmful depending on tissue stress state G Removal of tumor stress-adaptation capacity Secondary but therapeutically relevant where autophagy supports tumor survival.
7 EMT migration invasion metastasis EMT markers ↓; migration ↓; invasion ↓; metastatic traits ↓ Could affect normal wound-healing pathways at sufficient exposure G Anti-metastatic phenotype Strong preclinical relevance; not yet clinically validated.
8 Angiogenesis Pro-angiogenic signaling ↓ Physiologic angiogenesis may be affected in repair contexts G Reduced tumor vascular support Best treated as secondary/contextual unless a specific cancer model demonstrates angiogenesis as the dominant effect.
9 PARP1 trapping and BRCA synthetic lethality PARP1 trapping ↑; BRCA-mutated vulnerability ↑ DNA repair stress possible in proliferating normal cells R/G DNA-repair vulnerability exploitation Mechanistically interesting and industry-relevant, but narrower than the general ROS and ubiquitin-ligase mechanisms.
10 Clinical Translation Constraint In-vitro potency does not guarantee tumor exposure; formulation-dependent activity Safety margin uncertain for systemic use; crude neem products are not equivalent to purified nimbolide G Limits clinical interpretation Major constraints are poor solubility, uncertain human PK, lack of oncology trials, botanical heterogeneity, and neem toxicity concerns.

P: 0–30 min R: 30 min–3 hr G: >3 hr
NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
6487- Nimb,    Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development
- Review, Var, NA
TumCP↓, Apoptosis↓, TumMeta↑, angioG↓, *antiOx↑, *eff↑, Apoptosis↑, MOMP↑, CDK1↓, TumCCA↑, MAPK↓, JAK2↓, STAT3↓, PI3K↓, Akt↓, TumCP↓, *NRF2↑, NF-kB↓, GSK‐3β↑, Wnt↓, β-catenin/ZEB1↓, chemoPv↑, Bcl-xL↓, Bcl-2↓, survivin↓, Cyt‑c↑, BAX↑, BID↑, cl‑Casp↑, P53↑, DR5↑, DR4↑, ROS↑, lipid-P↑, MDA↑, MMP2↓, MMP9↓, uPA↓, ICAM-1↓, CXCR4↓, CXCR2↓, angioG↓, BBB↑,
6486- Nimb,    Nimbolide: promising agent for prevention and treatment of chronic diseases
- Review, Var, NA - Review, AD, NA
*other↝, *Inflam↓, AntiCan↑, *Bacteria↓, *AntiViral↑, *neuroP↑, *hepatoP↑, *ROS?, *NRF2↑, *HO-1↑, *TLR4↓, *NF-kB↓, *AChE↓, *Aβ↓, *GSK‐3β↓, *LDL↓, *DNAdam↓, *lipid-P↓, *antiOx↑, *SOD1↑, *GSH↑, *IL6↓, *IL1β↓, *STAT3↓, *GPx↑, *Catalase↑, *MDA↓, *AntiDiabetic↑, *HDL↓, *MCP1↓, *VEGF↓, *MMP9↓, *GutMicro↑, TumCP↓, TumCCA↑, TumCMig↓, NF-kB↓, ROS↑, PI3K↓, Akt↓, mTOR↓, ERK↓, EMT↓, TumMeta↓, ChemoSen↑, eff↑, selectivity↑, CDK4↓, CDK6↓, Wnt↓, β-catenin/ZEB1↓, STAT3↓, MMP2↓, Sp1/3/4↓, AP-1↓, P21↑, *AntiArt↑, *IL23↓, *IL17↓, *IFN-γ↓, *HSP70/HSPA5↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

lipid-P↑, 1,   MDA↑, 1,   ROS↑, 2,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↓, 1,   Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Bcl-xL↓, 1,   BID↑, 1,   cl‑Casp↑, 1,   Cyt‑c↑, 1,   DR4↑, 1,   DR5↑, 1,   MAPK↓, 1,   MOMP↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK4↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   ERK↓, 1,   GSK‐3β↑, 1,   mTOR↓, 1,   PI3K↓, 2,   STAT3↓, 2,   Wnt↓, 2,  

Migration ⓘ

AP-1↓, 1,   MMP2↓, 2,   MMP9↓, 1,   TumCMig↓, 1,   TumCP↓, 3,   TumMeta↓, 1,   TumMeta↑, 1,   uPA↓, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

CXCR2↓, 1,   CXCR4↓, 1,   ICAM-1↓, 1,   JAK2↓, 1,   NF-kB↓, 2,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoPv↑, 1,  
Total Targets: 52

Pathway results for Effect on Normal Cells:


NA, unassigned ⓘ

AntiArt↑, 1,  

Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   HDL↓, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NRF2↑, 2,   ROS?, 1,   SOD1↑, 1,  

Core Metabolism/Glycolysis ⓘ

LDL↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↓, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 1,  

Proliferation, Differentiation & Cell State ⓘ

GSK‐3β↓, 1,   STAT3↓, 1,  

Migration ⓘ

MMP9↓, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

IFN-γ↓, 1,   IL17↓, 1,   IL1β↓, 1,   IL23↓, 1,   IL6↓, 1,   Inflam↓, 1,   MCP1↓, 1,   NF-kB↓, 1,   TLR4↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   hepatoP↑, 1,   neuroP↑, 1,  

Infection & Microbiome ⓘ

AntiViral↑, 1,   Bacteria↓, 1,  
Total Targets: 39

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:250  Target#:226  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page